Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05873439 | Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC | completed | Early Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04298606 | A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence | completed | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04049474 | Bronchoscopic Cryo-Immunotherapy of Lung Cancer | completed | Early Phase 1 | 21 | NYU Langone HealthOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT02978196 | 99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC | completed | Early Phase 1 | 34 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03858491 | Pharmacokinetic Boosting of Osimertinib(OSIBOOST) | completed | Early Phase 1 | 11 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT01781741 | Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Early Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT03158883 | UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients | completed | Early Phase 1 | 8 | Megan Daly, MDOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02357836 | Neoadjuvant Itraconazole in Non-small Cell Lung Cancer | completed | Early Phase 1 | 13 | University of Texas Southwestern Medical CenterOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03224871 | UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | completed | Early Phase 1 | 3 | University of California, DavisOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02628080 | Atovaquone as Tumour HypOxia Modifier(ATOM) | completed | Early Phase 1 | 46 | University of OxfordOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01666353 | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT02463994 | A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | completed | Early Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT00221169 | Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer | completed | Early Phase 1 | 31 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Feb 5, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Apr 1, 2026source: clinicaltrials